Directed issue of units to guarantors and registration of shares from both the rights issue and the directed issue

Copenhagen, Denmark, 5 July 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  · The Board of Directors in Brain+ has carried out a directed issue of units as compensation to guarantors of the Company’s unit rights issue in June   · The increase in share capital and in number of shares from the rights issue and the directed issue has subsequently been registred with the Danish Business Authority  · An application to have the new shares and the warrants of series TO 4 admitted for trading on Nasdaq First North Growth Market Denmark will be submitted for expected first day of trading on 11 July 2024 

Brain+ A/S publishes the outcome of its rights issue of units

Copenhagen, Denmark, June 27 2024 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The public subscription period in Brain+ A/S’ (“Brain+” or the “Company”) rights issue of units with pre-emptive subscription rights for the Company’s existing shareholders ended on June 24, 2024. The rights issue was subscribed to a total of 46.5%, including pre-subscription commitments, which together with partly activated bottom-up guarantee commitments and activated top-down guarantee commitments, resulted in the rights issue being finally subscribed to 66.6%. This will provide Brain+ with proceeds of approximately DKK 6.0 million before repayment of the bridge loan received by the Company end May 2024 and deduction of transaction related costs. The outcome of the rights issue of units will ensure Brain+ net proceeds to fund the continued execution of its UK focused go-to-market plan towards commercial introduction of the UK CST-Assistant v.2.0 by end Q3 2024.

Brain+ obtains additional guarantee commitment in its ongoing rights issue

Copenhagen, Denmark, 24 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or the “Company”) announces that the Company has agreed to expand the top-down guarantee tranche in the ongoing rights issue of units of approximately DKK 8.94 million (the “Rights Issue”) with additional DKK 200,000. The top-down guarantee is to the same terms as members from the board and management of Brain+ have agreed to. In total, top-down guarantees now amount to DKK 928,822 and the Rights Issue is covered 66.6% by pre-subscription and guarantee commitments, corresponding to approximately DKK 6.0 million in pre-secured gross proceeds to Brain+.

Last day for subscription in the ongoing rights issue

Copenhagen, Denmark, 21 June, 2024 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Monday, 24 June 2024, is the last day for subscription in Brain+ A/S’ (“Brain+” or the “Company”) ongoing issue of units with pre-emptive rights for the Company’s existing shareholders (the “Rights Issue”). The Rights Issue can, upon full subscription, provide Brain+ with approximately DKK 8.94 million in proceeds before deduction of transaction related costs. Please note that some banks and nominees have deadlines for subscription earlier than 24 of June. Shareholders should therefore check with their bank or nominee, whether they apply an earlier deadline for subscription.

Correction - Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue

The company announcement made by Brain+ A/S at 12:37 today contained an inadvertent error in that the DKK 150,000 subscription from management is a general subscription commitment and does not therefore increase the guaranteed coverage of the rights issue. That coverage is correctly stated as currently being 64.4%. The correct company announcement follows below: Copenhagen, Denmark, 20 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP) This announcement constitutes inside information that Brain+ A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU no. 596/2014). The information was submitted for publication by the contact person below on 20 June 2024. Brain+ A/S (“Brain+” or the “Company”) announces that the Company has agreed to expand the top-down guarantee tranche in its ongoing rights issue of units (new shares and warrants of series TO 4) of up to DKK 8.94 million (the “Rights Issue”). The expansion is to accommodate an investment commitment of approximately DKK 372,000 (€50,000) from 5P Future of Health Beteiligungs GmbH, a newly formed and health tech specialized German investment boutique. The top-down guarantee is on the same terms as members of the board and management of Brain+ have agreed to. In total the top-down guarantee tranche now amounts to approximately DKK 728,822 and the Rights Issue is covered to 64.4% by pre-subscription and guarantee commitments.

Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue

Copenhagen, Denmark, 20 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP) This announcement constitutes inside information that Brain+ A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU no. 596/2014). The information was submitted for publication by the contact person below on 20 June 2024. Brain+ A/S (“Brain+” or the “Company”) announces that the Company has agreed to expand the top-down guarantee tranche in its ongoing rights issue of units (new shares and warrants of series TO 4) of up to DKK 8.94 million (the “Rights Issue”). The expansion is to accommodate an investment commitment of approximately DKK 372,000 (€50,000) from 5P Future of Health Beteiligungs GmbH, a newly formed and health tech specialized German investment boutique. The top-down guarantee is on the same terms as members of the board and management of Brain+ have agreed to. In total the top-down guarantee tranche now amounts to approximately DKK 728,822 and the Rights Issue is covered to 64.4% by pre-subscription and guarantee commitments. Furthermore, CEO Kim Baden-Kristensen and CFO Hanne Vissing Leth have, in addition to their pre-subscription and top-guarantee commitments, subscribed for an additional aggregated amount of approximately DKK 150,000 without support of unit rights. This brings the total coverage of the Rights Issue up to 66.1%, corresponding to total secured gross proceeds of DKK 5.95 million to Brain+.

The subscription period in Brain+ unit rights issue begins today

Copenhagen, Denmark, 11 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Today, 11 June 2024, the subscription period commences in Brain+ A/S´ (“Brain+” or the “Company”) issue of units (bundle of new shares in Brain+ and warrants of series TO 4) with pre-emptive subscription rights for the Company’s existing shareholders (the “Rights Issue”). The subscription period runs until and including 24 June 2024. The Rights Issue can, upon full subscription, provide the Company with approximately DKK 8.94 million before deduction of transaction related costs and without counting proceeds from the exercise of the TO 4 warrants.

Brain+ A/S informs of the last day of trading in its shares including preferential rights to subscribe in the upcoming unit rights issue

Copenhagen, Denmark, 4 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.  The Board of Directors of Brain+ A/S (“Brain+” or “the Company”) decided on 7 May 2024 to carry out a rights issue of units (new shares and warrants of series TO 4) with preferential subscription rights for the Company’s existing shareholders (the “Rights Issue”). The Rights Issue was approved by the Annual General Meeting on 22 May 2024. The offer price for new shares in the Rights Issue is DKK 0.08 per share to raise up to DKK 8.94 million in gross proceeds to Brain+, and the subscription period will commence on Tuesday 11 June 2024 and last until and including 24 June 2024. The record date in the VP-system for obtaining preferential rights to subscribe in the offer is on 10 June 2024, which means that the last day of trading in Brain+ shares including the preferential rights is 6 June 2024. From 7 June 2024, Brain+ shares will be trading without the rights, which from the same date will be admitted to trading under ISIN DK0062955415 with the name Brain+ UR. 

Brain+ A/S: Publication of investment brochure

Copenhagen, Denmark, 31 May 2024 – Brain+ A/S (Nasdaq First North: BRAINP) The Board of Directors of Brain+ A/S (“Brain+” or the “Company”) decided on 7 May 2024, with following approval from the Annual General Meeting held on 22 May 2024, to carry out a rights issue of units (the “Rights Issue”). The subscription period in the Rights Issue commences on 11 June 2024 and lasts until and including 24 June 2024. Brain+ has today published an investment brochure with information about the Company, its business, products and strategy, and about the Rights Issue. The investment brochure is attached to this announcement and is also available on the websites of Brain+ and Sedermera Corporate Finance AB. For complete information about the Rights Issue, please see Brain+’ company announcement from 7 May 2024 (https://websolutions.ne.cision.com/releasedetail.html?releaseIdentifier=790256354D5B017F).

Minutes of Annual General Meeting in Brain+

Copenhagen, Denmark, May 22, 2024 – Brain+ A/S (Nasdaq First North: BRAINP) On 22 May 2024, at 8:00 AM (CEST) the Annual General Meeting of 2024 was held in Brain+ A/S, CVR. No. 36439440 (the “Company” or “Brain+”) at the Company’s registered address at: Købmagergade 53, 3 1150 København K, Denmark. At the meeting the Management of the Company as well as the Board of Directors were present. In addition, the Company had received proxies and postal votes, and a total of 19.8% of shareholder votes were represented at the meeting. The General Meeting was called for with the following agenda: 1. Election of chairman of the meeting. 2. The Board of Directors' report on the Company's activities during the past account year. 3. Approval of the Annual Report for 2023. 4. Resolution as to the appropriation of profits or the covering of losses according to the approved annual accounts. 5. Election of members of the Board of Directors. 6. Election of auditor. 7. Motions or resolutions, if any, from the Board of Directors or the shareholders:     a) Proposal to reduce the share capital to cover losses and at the same time to reduce the nominal value per share from DKK 0.10 to DKK 0.08.     b) Proposal to increase the Company’s share capital and to issue warrants as part of an announced unit rights issue.     c) Proposal to authorise the Board of Directors to increase the Company’s share capital and to issue warrants.     d) Proposal to amend the Company’s articles of association. 8. Approval of authorisation of the Chairman of the meeting.

Brain+ A/S convenes the Annual General Meeting

Copenhagen, Denmark, April 28, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) Notice is hereby given for the Annual General Meeting for 2024 in Brain+ A/S, CVR. No. 36439440 (“the Company”) to be held on Wednesday, 22 May 2024 at 8:00 AM (08:00 CEST). The Annual General Meeting will be held at the Company’s registered address at: Købmagergade 53, 3., DK-1150 København K.

Brain+ publishes its Annual Report for 2023 – A year of market access, product development and a refocused commercial strategy

Copenhagen, Denmark, April 28, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)  Brain+ A/S (“Brain+”), a company pioneering health tech solutions for better dementia management, today published its Annual Report for 2023. The report emphasizes the company’s financial and business performance during the reporting year and its outlook and objectives for 2024.   To secure the necessary funding for the company’s continued business activities and the execution of its UK focused commercial plan, Brain+ earlier today announced a partially secured unit rights issue of up to DKK 8.9 million with pre-emptive rights for its existing shareholders (see Company Announcement “Brain+ A/S announce a partially secured rights issue of units of approximately DKK 8.94 million to fund operations and execution of its UK commercialization plan.”)  

Brain+ A/S announce a partially secured rights issue of units of approximately DKK 8.94 million to fund operations and execution of its UK commercialization plan

Copenhagen, Denmark, 7 May 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  This announcement constitutes inside information that Brain+ A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU no. 596/2014). The information was submitted for publication by the contact person below on 7 May 2024.  NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.  The Board of Directors of Brain+ A/S (“Brain+” or “the Company”) has today, on 7 May 2024, decided to carry out a rights issue of units, with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The units consist of new shares and warrants of series TO 4 in Brain+. The Rights Issue is subject to approval at the Annual General Meeting to be held on 22 May 2024 (the “AGM”). Notice to the AGM will be published in a separate company announcement.  If the Rights Issue is fully subscribed, Brain+ will receive approximately DKK 8.94 million in gross proceeds. The subsequent exercise of warrants of series TO 4 in September 2024 can, if fully exercised, provide the Company with additionally DKK 9.14 million. The Rights Issue is secured in advance to approximately 60.2 percent, corresponding to secured gross proceeds to Brain+ of DKK 5.38 million, through subscription commitments from existing shareholders and guarantee commitments. In connection with the Rights Issue, Brain+ has entered into a loan agreement of DKK 2.00 million, which is to be received in May 2022 pending approval of the Rights Issue at the AGM and to be repaid upon completion of the Rights Issue.  

Brain+ releases preliminary annual financial statements for 2023

Copenhagen, Denmark, 30 April 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  · Brain+’ preliminary financial results for 2023 shows a gross profit of DKK 2.4 million and a net result of DKK -19.1 million  · Brain+’ management has maintained a tight cost control to extend the company’s financial runway as much as possible and ensure operational momentum in its early phase of product commercialization  · On 31 December 2023, the company’s cash and cash equivalents amounted to DKK 3.1 million.   · In March 2024, Brain+ raised DKK 2.5 million in net proceeds from a 91% exercise of its TO 3 warrants and announced that work is ongoing towards a decision on the next funding step to secure the company’s operations and UK commercialization plan   · As previously announced, Brain+ will publish its full Annual Report for 2023 on 7 May 2024  

Brain+ announces a change in its Financial Calendar for 2024

Copenhagen, Denmark, April 29, 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  · Brain+ will publish its Annual Report for 2023 on May 7, 2024   · On April 30, 2024, the company will issue an announcement of its un-audited Annual Financial Statements for 2023  

Brain+ announces registration of directed issue with the Danish Business Authority

Copenhagen, Denmark, April 10, 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · New shares from the directed issue to guarantors of the series TO 3 warrant exercise have been registered with the Danish Business Authority (DA: Erhvervsstyrelsen) · The new shares are expected to commence trading on Nasdaq First North Copenhagen on April 12, 2024

Brain+ announces registration of series TO 3 warrant exercise with the Danish Business Authority

COMPANY ANNOUNCEMENT · New shares from the exercise of Brain+ warrants of series TO 3 have been registered with the Danish Business Authority (DA: Erhvervsstyrelsen) · Brain+ interim shares (IA/midlertidig aktie) will be converted into common shares and commence trading on Nasdaq First North Copenhagen on April 11, 2024 · Registration and commencement of trading of shares from the directed issue will be separate

Brain+ announces the outcome of its series TO 3 warrant exercise and decision to carry out a directed share issue to cover guarantor commitments

Copenhagen, Denmark, March 26, 2024– Brain+ A/S (Nasdaq First North: BRAINP) · 91% of the warrants of series TO 3 have been subscribed for, securing Brain+ approximately DKK 2.9 million in gross proceeds · 18,198,975 warrants of series TO 3, or 64% of the total outstanding, were exercised to subscribe for 18,198,975 new shares in the company · Guarantor commitments from shareholders covered an additional 27% of the offering · To cover the guarantor commitments, the board of directors of Brain+ today decided to carry out a directed issue of 7,787,874 new shares on the same terms as for the TO 3 warrant exercise  

Brain+ A/S specifies how to get TO 3 warrant compensation

Copenhagen, Denmark, March 26, 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · As announced on March 7, 2024, compensation is offered to investors who have exercised TO 3 warrants and suffered a loss because of the decision to remove the upper and lower limits for the exercise price

Brain+ A/S announces last day of trading in its warrants of series TO 3

COMPANY ANNOUNCEMENT Copenhagen, Denmark, 20 March 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · Today, 20 March 2024 is the last day of trading in the warrants of series TO 3 · The exercise price of the warrants is DKK 0.11 and the exercise period runs until and including Friday 22 March 2024  

Brain+ announces that 77% of its warrants of series TO 3 are now covered by commitments

Copenhagen, Denmark, 15 March 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · Firm commitments of exercise and guarantees from management and larger shareholders now cover 71% of the 28,542,348 outstanding warrants of series TO 3    · Soft exercise commitments cover an additional 6% · Less than halfway into the exercise period, coverage of warrants of series TO 3 already exceeds the outcome of 74% exercise and guarantor coverage of warrants of series TO 2 in October 2023

Brain+ announces that 58% of its warrants of series TO 3 are covered by early commitments

COMPANY ANNOUNCEMENT · Members of management and board members/observers have committed to exercise all their TO 3 warrants and provide additional guarantee commitments, covering 6% of the issue   · The company’s largest shareholders have so far provided firm commitments to exercise warrants and provide guarantees for a total of 52% of the issue · As earlier announced, the exercise price for the warrants of series TO 3 is DKK 0.11 and the exercise period runs from 11 March 2024 to 22 March 2024 · If all warrants are exercised/guaranteed, it will add DKK 3.14 million and three (3) months to Brain+’s financial runway · In parallel with the warrant exercise, longer-term funding options are being evaluated to optimize the company’s operations and the return to its shareholders, including ways to benefit from the gap between public and private equity market valuations of near-commercial health tech companies

Brain+ A/S announces amended terms for upcoming TO 3 warrant exercise

Brain+ A/S (Nasdaq First North: BRAINP) - This announcement constitutes inside information that Brain+ is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was provided by the contact person below for publication on 7 March 2024 · The previously announced minimum and maximum exercise price levels for Brain+  warrants of series TO 3 have been eliminated · With the amended terms, the exercise price for warrants of series TO 3 has been set at DKK 0.11 per new Brain+ share subscribed for, which represents a 33% discount to the closing price of the Company’s existing shares on 6 March 2024   · The exercise period for the TO 3 warrants have been changed from previously announced Friday 8 March – Friday 22 March 2024 to Monday 11 March – Friday 22 March 2024 · Compensation will be available to investors who exercise warrants of series TO 3 and realise a loss in doing so as a result of the amended terms

Brain+ nominates an international digital health industry expert and experienced investor profile as new chairman candidate

COMPANY ANNOUNCEMENT  Brain+ A/S (Nasdaq First North: BRAINP) - This information is information that Brain+ A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on February 12, 2024  · Tim Juergens, who is a strong believer in the potential of digital therapeutics, will be up for election at Brain+’ Annual General Meeting on May 15, 2024, and until then act as active board observer and strategic partner to management  · In the interim, Johan Luthman, who has been on the company’s board since September 2022, takes the role as chairman   

Brain+ announces a change in the Chief Financial Officer position

COMPANY ANNOUNCEMENT · Hanne Leth Hillman, who has served as interim CFO since 1 May 2023, will continue in the role as the company’s new CFO Copenhagen, Denmark, 9 January 2024 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+’s chairman to step down

Brain+ A/S (Nasdaq First North, Denmark: BRAINP) This information is information that Brain+ A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on December 14, 2023

Brain+ gets public grant of DKK 3.5 million to scale the implementation of CST-Therapist Companion in Denmark

Brain+ A/S (Nasdaq First North, Denmark: BRAINP) This information is information that Brain+ A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on December 14, 2023 · Final grant approval received from the Danish Business Authority following a successful project evaluation and review process    · This non-dilutive funding will scale the commercial implementation of Brain+’ digital tool and enable a more effective delivery of Cognitive Stimulation Therapy (CST) in Danish municipalities to benefit people with dementia · Dementia institutions from seven (7) Danish municipalities, the DanAge (Ældresagen), the Danish Alzheimer’s Association and Konsulatet for Fællesskab are project partners · The grant is an important milestone and a validation of the relevance and commercial potential of CST-Therapist Companion · Brain+ can receive the first payment under the grant project in Q2 2024

Brain+ nominated to CO-PI grant of up to DKK 3.5 million to scale implementation of CST-Therapist Companion into dementia care in Denmark

· The grant nomination is a strong validation of the relevance and potential of CST-Therapist Companion to digitally support an effective and high-quality delivery of Cognitive Stimulation Therapy (CST) for improved dementia care in Denmark – and abroad · In the project, Brain+ will work together with seven municipalities, the Danish Alzheimer’s Association and DanAge (Ældresagen) · The project has a starting date in Q4 2023 and first grant money can be received in H1 2024 · Final grant approval awaits an ongoing validation and budget review process with deadline mid-December  

Brain+ announces a change to its Board of Directors

  · Effective from end of November 2023, Betül Susamis Unaran, member of the Board of Directors of Brain+, has resigned from her position for professional reasons

Brain+ announces registration with the Danish Business Authority and first day of trading of new shares

· The Brain+ series TO 2 warrant exercise and directed share issue have been registered with the Danish Business Authority (Danish: Erhvervsstyrelsen) · Interim shares (Danish: IA/midlertidig aktie) from the warrant exercise will be converted into common Brain+ shares (ISIN DK0061670205) and, following conversion, together with shares from the directed issue commence trading on Nasdaq First North Copenhagen on 30 October 2023 Copenhagen, Denmark, 24 October2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ announces the outcome of its series TO 2 warrant exercise and decision to carry out a directed share issue to cover guarantor commitments

COMPANY ANNOUNCEMENT · Brain+ announces that 74.3% of its warrants of series TO2 have been subscribed for, securing the company approximately DKK 4.2 million in gross proceeds · The exercise rate amounted to 67.4% of the total outstanding number of warrants with 19,228,798 warrants of series TO 2 exercised to subscribe for 19,228,798 new shares in the company · Guarantor commitments covered an additional 6.9% of the offering · To cover the guarantor commitments, the board of directors today decided to carry out a directed issue of 1,970,766 new shares on the same terms as for the TO 2 warrant exercise   Copenhagen, Denmark, 18 October2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ announces additional commitments in the ongoing exercise of warrants of series TO 2 to reach now a coverage of almost 50%

· Brain+ has received additional new commitments from existing shareholders to exercise approximately 3.5 million warrants of series TO 2 · Including the previously announced commitments, total commitments in the TO 2 warrant exercise now covers almost 50% of the total number of warrants, corresponding to approximately DKK 2.7 million in proceeds Copenhagen, Denmark, 12 October 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ A/S announces last day of trading in warrants of series TO 2

Copenhagen, Denmark, 12 October 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Today, 12 October is the last day of trading in the warrants of series TO 2 · The exercise period for the warrants runs until 16 October 2023 and so far, 36% of the warrant proceeds have been committed

Minutes of the Extraordinary General Meeting

Copenhagen, Denmark, October 11, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ announces commitments from its largest shareholders in the ongoing exercise of warrants of series TO 2

COMPANY ANNOUNCEMENT Copenhagen, Denmark, 10 October 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Large Brain+ shareholders have committed to exercise warrants for DKK 1.6 million or 28% of the total outstanding · Members of board and management have doubled their announced commitments to DKK 0.4 million or 7% of the total outstanding, providing DKK 0.2 million in guarantees,    · The exercise price for the warrants of series TO 2 has been set at DKK 0.20 and the exercise period runs from 2 - 16 October 2023

Members of Brain+’ board and management commit to exercise all their warrants of series TO 2

COMPANY ANNOUNCEMENT Copenhagen, Denmark, 2 October 2023 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. · CEO & Co-founder Kim Baden-Kristensen, Chairman of the board Anders Härfstrand, board member Johan Luthman, and CFO Hanne Leth Hillman have committed to exercise all their warrants of series TO 2 to an aggregated amount of DKK 0.2 million · The exercise price for the warrants of series TO 2 has been set at DKK 0.20 and the exercise period runs from 2 - 16 October 2023

Brain+ A/S announces the exercise price for its warrants of series TO 2

COMPANY ANNOUNCEMENT Copenhagen, Denmark, September  29, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. · The exercise price of the TO 2 warrants has been set at DKK 0.20 · The exercise period for the TO 2 warrants runs from 2-16 October 2023 · The TO 2 warrants are tradable with the last day of trading set to 12 October 2023

Notice of Extraordinary General Meeting

Summary of H1 2023 report: Brain+ has closed new sales contracts, built key customer engagement, developed a new product concept, achieved technology validations and secured new funding

Brain+ A/S (BRAINP) - Company Announcement Thursday, August 31, 2022, 8:30 CET Today, Brain+ has released its financial report for the period 1 January - 30 June 2023 (unaudited) including a business update for the year to date.

Brain+ A/S carries out a directed issue as compensation to guarantors of its unit rights issue

COMPANY ANNOUNCEMENT Copenhagen, Denmark, June 12, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

Brain+ A/S announces the first day of trading for the new shares and warrants from its rights issue

COMPANY ANNOUNCEMENT Copenhagen, Denmark, June 9, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

Brain+ A/S announces a delay of the first day of trading for the new shares from its rights issue

Brain+ A/S published the outcome of its rights issue of units

COMPANY ANNOUNCEMENT Copenhagen, Denmark, May 30, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The subscription period in Brain+ A/S’ (“Brain+” or the “Company”) rights issue of units with pre-emptive subscription rights for existing shareholders, in which the public also was given the opportunity to participate, ended on May 25, 2023. The rights issue was subscribed to a total of approximately 88 percent, including pre-subscription and guarantee commitments. Brain+ will thus be provided proceeds of approximately DKK 13.8 million before deduction of transaction related costs. As a result of the outcome, the option of an over-allotment issue will not be used. The outcome of the rights issue of units ensures that Brain+ can continue investing in the commercial build-up for its first marketed digital dementia product and in maturing its clinical pipeline of more advanced product options. Formal decision on unit allocation is estimated to take place on May 31, 2023.

Minutes of the Annual General Meeting 2023 in Brain+ A/S

On Friday 26[th] of May at 08:00 CET, Brain+ A/S held its Annual General Meeting. The meeting was held at the company’s home address at Købmagergade 53, 3. 1150 Copenhagen with the following agenda:

Notice of Annual General Meeting of Brain+ A/S

Invitation to Annual General Meeting The shareholders of Brain+ A/S are hereby invited to attend the Annual General Meeting scheduled for Friday, 26th of May 2023, at 08:00 am. The general meeting will take place at the company’s address at Købmagergade 53, 3., 1150 Copenhagen as a physical event.

The subscription period in Brain+ rights issue begins today

COMPANY ANNOUNCEMENT Copenhagen, Denmark, May 10, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE

Brain+ A/S publishes supplement to prospectus

Brain+ publishes its Annual Report 2022, highlighting important milestones and financial performance as expected

COMPANY ANNOUNCEMENT  Copenhagen, Denmark, April 28, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+, a digital dementia therapeutics company, has today published its annual report for 2022, including  

Annual Report 2022 for Brain+ A/S

Brain+ annual report for 2022 is now available on the Company´s website

Brain+ A/S (BRAINP) announces management changes

COMPANY ANNOUNCEMENT Copenhagen, Denmark, April 25, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ informs that its Chief Financial Officer (“CFO”), Bertil S. Jessen, will be taking a one-year leave of absence for family reasons starting in May 2023.

New UK Labour government will focus on healthtech and dementia treatment as part of UK healthcare reform

Copenhagen, Denmark, 12 July 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · Building a National Health Service (NHS) fit for the future is a top priority for the new UK Labour government · As part of their healthcare plan, Labour wants to harness the power of healthtech to offer better disease prevention and management and put Britain at the forefront of dementia treatment    · Brain+’ pipeline of healthtech solutions for better dementia management have offerings perfectly aligned with the new political healthcare agenda in the UK · The planned launch of the CST-Assistant, Brain+’ first product into the UK market, by end Q3 2024 is set to occur on the backdrop of a highly supportive political environment

The CST Assistant v2.0 for Cognitive Stimulation Therapy (CST) now released in Denmark

Copenhagen, Denmark, 9 July 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · The new version of the CST Assistant software solution offers significant upgrades in terms of content, user interface and functionality   · Available for existing customers and ready for introduction to new sales leads among Danish municipalities   · The process of UK medical device certification of the English version of the CST Assistant v2.0 is progressing towards planned UK release end Q3 2024

Brain+ hires UK health tech rising star as Chief Commercial Officer

Copenhagen, Denmark, 28 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · Devika Rani Wood has been appointed as Chief Commercial Officer to build and drive growth of Brain+’ commercial business in the UK   · Devika is an award winning executive healthtech leader and brings extensive UK-focused health tech experience from roles at ORCHA Health LTD, AXA Health, and Vida   · The new hire substantially strengthens Brain+’ commercial profile to accelerate the adoption of the company’s dementia management solutions into the UK National Health Service and scale international sales 

Brain+ establishes UK subsidiary

Copenhagen, Denmark, 17 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · With the incorporation of Brian+ UK Limited, Brain+ has established legal presence in the UK · The UK is currently the most mature and attractive market for the company’s software-based dementia therapies · The establishment of a legal UK entity opens access to · commercial opportunities in the UK healthcare system, and · funding resources, including UK healthcare grants · The move is an important step in the execution of Brain+’ UK focused commercial strategy

The CST-Assistant v2.0 is now ready for release in Denmark and on track for release in the UK end of Q3 2024

Copenhagen, Denmark, 14 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · The development of all technical features and of high-quality, curated and adaptable CST content for the CST-Assistant v2.0 has been completed · The new version of the CST-Assistant is a considerable upgrade of the product to meet key pain points and needs of CST therapists to support and scale the delivery of Cognitive Stimulation Therapy (CST) to people with dementia · The CST-Assistant v2.0 will be released in Denmark later in June and made available for partners in the COPI implementation project to gain relevant user information · The completion of the CST-Assistant v2.0 is a key step in the preparation of UK market entry of the product as a certified medical software in Q3 2023

First steps taken to integrate CST-Assistant training with the formal CST-education in DK – a key market gateway milestone, also paving way for the UK

Copenhagen, Denmark, 3 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  · Under the CO-PI granted project, Brain+ has held the first CST-Assistant training sessions to test the integration of the product with the formal CST education in Denmark   · The objective is to establish a new CST-education standard, which includes in depth introduction to and hands-on training in the CST-Assistant to facilitate an easier transition from education to CST practice   · Educating new CST therapists based on the CST-Assistant is an important gateway for greater customer reach and a key step towards a complete Brain+ full-service CST offering   · Dialogue with UK stakeholders to develop a similar combined education program has begun based on the Danish model    

Brain+’ invites to online investor event with new Chairman

Copenhagen, Denmark, 24 May 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  · Monday, 27 May 2024 at 16:30 CEST, Brain+ hosts an investor meeting on the Stokk.io event platform: Brain+ investor-update-w-new-chairman/ (https://eur05.safelinks.protection.outlook.com/?url=https%3A%2F%2Fapp.stokk.io%2Fapp%2Fbrain%2Fevent%2F152%2Finvestor-update-w-new-chairman%2F&data=05%7C02%7Channe%40brain-plus.com%7C8b24e83467a6407e250c08dc7b2a6ee6%7Cf2f9babfec61480d81d3c163d28ca06a%7C0%7C0%7C638520669408978149%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=ySNDITm8fwcqDM3UsnTrqF4E%2F827vQLWdEY016Y%2BQjY%3D&reserved=0) · The event is an opportunity to e-meet the company’s new chairman, Tim Juergens, who was elected at the Annual General Meeting earlier this week and will participate in the investor meeting to present and answer questions · At the meeting, Brain+’ CEO and CFO will update on business activities and outlook, and present details on the upcoming partially secured Unit Rights Issue, approved earlier this week by the Annual General Meeting

Brain+ informs of progress on its UK focused proof-of-business strategy plan

Copenhagen, Denmark, 16 May 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · Supportive early user feedback from the ongoing AgeUK usability study of the CST-Assistant v2.0 to standardize Cognitive Stimulation Therapy (CST) · Application submitted for the CST-Assistant to be included on G-Cloud, the digital procurement platform for the UK National Health Service, NHS · Development and UK regulatory compliance of the English CST-Assistant v2.0 as medical software advancing as planned towards UK launch in Q3 2023 · Together with Quiddity, pre-commercial outreach to relevant UK NHS trusts has begun

Brain+ updates on implementation and scaling activities for its CST-Assistant in Denmark

Copenhagen, Denmark, May 2, 2024 – Brain+ A/S (Nasdaq First North: BRAINP)   · Upcoming v2.0 of the CST-Assistant is showcased today at the Dementia Days (2-3 May) 2024, the 3rd time Brain+ features at this primary annual dementia event in Denmark   · Danish usability study of the CST-Assistant with 5 municipalities and VIA University College completed in Q1 2024 with positive feedback and user insights being incorporated into v2.0    · Building on growing CST adoption, its pipeline of sales leads, show-casing and planned release of an upgraded CST-Assistant v2.0, Danish sales are expected to increase in 2024   · The DKK 3.5 million grant funded DK project for implementation and scaling of the CST-Assistant, partnered with 6 municipalities, the Danish Alzheimer’s Association and the DanAge Association, has advanced to CST therapist education and product implementation    · The CST-Assistant is being integrated into the official CST education for new therapists. The 2nd iteration of the ‘integrated CST education’ now starts being tested in the CO-PI project   

Brain+’ CST-Assistant cited in leading Nordic Life Science magazine as an impactful health tech intervention for managing dementia

Copenhagen, Denmark, 30 April 2024 – Brain+ A/S (Nasdaq First North: BRAINP)     · Health tech, A.I. and Computer-Brain interfaces are making an impact on CNS disease treatments, beyond the traditional pharmaceutical treatments. (NLS magazine)   · The Brain+ CST-Assistant, which enables software-based delivery of Cognitive Stimulation Therapy for people with dementia, is highlighted as an impactful health tech treatment (NLS magazine)   · While CST itself is an effective and globally recognized dementia therapy, the future holds potential for combining it with pharmaceutical treatments for even larger health effects.   

Successful educational CST course held with Malteser Germany based on the CST-Assistant

Copenhagen, Denmark, 26 April 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · The value of the CST-Assistant v1.0 in facilitating easier CST implementation, saving preparation time and supporting therapeutic delivery was confirmed in the course · Integrating the CST-Assistant in the German CST education is an important means for Brain+ to build user adoption and demand for the product · After the course, Brain+ has agreed to provide Malteser with free access to the CST-Assistant to support CST implementation in a test phase against data and user feedback · While Brain+ has a near-term commercial focus on the UK, the company is still committed to providing access to its CST-Assistant to support the adoption of CST for better dementia management in Germany  

Brain+ starts UK Pilot Project on CST-Therapist Companion in partnership with Age UK

· An important step in the company’s UK focused strategy plan building towards commercial release of CST-Therapist Companion and first sales later in 2024 · Age UK is the largest UK charity organization for seniors and a significant provider of Cognitive Stimulation Therapy (CST) to people with dementia · Two Age UK sites will each run a full CST program using a near-final English v 2.0 of CST-Therapist Companion to provide UK user feedback and cost-effectiveness data · Project output will feed into Medical Device certification of CST-Therapist Companion v2.0 for the UK market in Q2 and market release in Q3 2024

Brain+ strategy update: Focus on the UK to reach proof-of-business and commercial scaling in 2024-2025

· The UK is assessed to be the most attractive and accessible market for Brain+’ digital dementia solutions, of which CST-Therapist Companion is the first · An endorsing partnership is in place with Quiddity Health, who has the strongest track record of bringing digital health products to scale in the UK · Commercial focus on the UK National Health System (NHS), which accounts for +80% of the country’s healthcare spend · Value inflection points are proof-of-business in 2024 and commercial scaling in 2025 · Important 2024 milestones for CST-Therapist Companion v2.0: Q1: Start of UK usability trial in partnership with AgeUK Q2: Certification as a EU MDR Class 1 Medical Device   Q3: Full certification in accordance with specific UK requirements for digital health products Q3: UK commercial release (as a Medical Device) Q4: First contract(s) with local NHS Trusts · The strategy targets break-even for the UK business in late 2025 and for the company in late 2026

Brain+ partners with Quiddity Health, the #1 UK digital healthcare market specialist, to prepare UK market entry for CST-Therapist Companion

· Quiddity Health has a strong track-record of helping innovative digital therapeutic companies successfully enter the UK healthcare market and reach commercial scale    · Brain+ plans to have a UK version 2.0 of CST-Therapist Companion, its new digital solution to support effective dementia therapy, ready for UK market release in Q3 2024  · Initially, Quiddity Health will work with Brain+ to develop a targeted go-to-market plan for CST-Therapist Companion in the UK and build relevant pre-sale customer engagements   · Post market release, Quiddity Health will act as Brain+’ full scale commercial partner under a cost-efficient revenue sharing model to reach sales acceleration in the UK healthcare market   · First UK sale expected late Q4 2024 with buildup of pipeline for additional sales in Q1 2025 Copenhagen, Denmark, February 9th, 2024 – Brain+ A/S (Nasdaq First North: BRAINP) 

Brain+ signs two new Danish sales contracts on CST-Therapist Companion and updates on the product’s commercial potential

Investor News Copenhagen, Denmark, January 18, 2024 – Brain+ A/S (Nasdaq First North: BRAINP) · CST-Therapist Companion sales contract signed with Syddjurs municipality to deliver Cognitive Stimulation Therapy (CST) to people with dementia · First important repeat sale to Herning who has extended existing contract · Five ‘foot-in-the-door’ sales to Danish municipalities so far with a combined value of DKK 0.25 million · A total of 16 Danish municipalities have started using CST-Therapist Companion to deliver CST; under sales contracts, as participants in a usability study or as partners in the CO-PI grant funded implementation project · The sales potential for CST-Therapist Companion in Denmark is estimated at DKK 5-6 million over 1 to 2 years · The Danish sales potential is expected to increase to DKK 20-25 million, as CST adoption grow   · In 2024, Brain+’ commercial focus will be on the UK market, representing a 10x larger dementia market than in Denmark, higher CST adoption rates and established digital therapy reimbursement pathways · CST-Therapist Companion is expected ready for release in the UK in the 3rd quarter of 2024 with a first sale targeted for end 2024

Brain+ closes sales contract with Copenhagen municipality on CST-Therapist Companion to support dementia care and therapy

Investor News · The contract gives Copenhagen initial access to use CST-Therapist Companion in three dementia care facilities and has the potential to be expanded to a municipality-wide agreement · As the largest and most important municipality in Denmark, Copenhagen has extensive experience with CST and is a key reference customer that other Danish municipalities observe and follow · Brain+ now has engagements with 15 Danish municipalities who use CST-Therapist Companion as part of either sales contracts, usability trial participation or involvement in the CO-PI grant application for implementation and scaling of the product · It is still expected that more CST-Therapist Companion sales contracts will be closed before the end of 2023 Copenhagen, Denmark, December 11, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ and VIA University College start usability study on CST-Therapist Companion in Denmark

INVESTOR NEWS · Therapists from 5 Danish municipalities will participate in the study and deliver Cognitive Stimulation Therapy (CST) to people with dementia, using the new version of Brain+’ digital CST-Therapist Companion. · CST-Therapist Companion offers time effective and tailored high-quality delivery of CST, and the study objective is to get structured user feedback on the content and functionalities of the product.   · The usability study is expected to complete by mid-December with final results available in January 2024 to feed into the completion and medical device certification of CST-Therapist Companion v2.0. · CST-Therapist Companion v2.0 is scheduled for commercial release in Denmark in Q2 2024 to be followed by releases in UK and Germany. Copenhagen, Denmark, 14 November 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ presents its unique digital CST offerings at two key European dementia conferences in October

· At the 33[rd] Alzheimer’s Europe conference, Brain+ shares insight and initial data from its recent work to validate tailored content for its CST-Therapist Companion v 2.0 product aimed to reduce variability in CST outcomes · At the annual meeting in INTERDEM, the most important pan-European network of researchers and clinicians disseminating psychosocial interventions in dementia, Brain+ presented its distinctive approach to digital delivery of CST · Brain+ is gaining recognition among patient groups, clinicians and researches as a key opinion leader on digitally delivered psychosocial, non-pharmaceutical interventions for the treatment of dementia Copenhagen, Denmark, 16 October, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Commercial outlook and potential impact of grants and partnering activities

Copenhagen, Denmark, 12 October 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · The 4th quarter of the year is “buying season” for Danish municipalities, which Brain+ expects to translate into 3-4 new sales contracts on its digital offering, CST-Therapist Companion · Brain+ has applied for new grants and ECB equity funding of a total of DKK 67 million, including a DKK 20 million EIC Accelerator grant with a potential pre-payment of 45% at project start, planned for 1[st] quarter 2024. Answers on grant applications are all expected in 2023. · Brain+ is in progressed dialogues with major pharma players active in the Alzheimer’s dementia field, about co-development in international markets

Copenhagen municipality sees potential in Brain+’ CST-Therapist Companion to deliver Cognitive Stimulation Therapy (CST) in the municipality’s nursing homes

Copenhagen, Denmark, October 11, 2023 - Brain+ A/S (Nasdaq First North: BRAINP) · Copenhagen is also one of the Danish municipalities with the most extensive experience with CST as a treatment offer for people with dementia · Stakeholders from Copenhagen municipality have given input to the development of CST-Therapist Companion, and the product has now been through an extensive technology review with the municipality’s IT department to verify that the product lives up to their high security and quality standards · Copenhagen is the largest municipality in Denmark and has about 7,000-7,500 people living with dementia, corresponding to about 12% of the Danish total of 90.000 people with dementia

Experienced life science profile and largest investor joins the Brain+ team as Strategic Partnerships Advisor to accelerate pharma partner deals

Brain+ releases new version of its CST-Therapist Companion dementia product with updated user features

Copenhagen, Denmark, 4 October  2023 – Brain+ A/S (Nasdaq First North: BRAINP) · A version 1.2 of CST-Therapist Companion with improved user features has been made available for municipal customers in Denmark · The update is based on user feedback following the introduction of CST-Therapist Companion v1.0 and the use of the product in dementia care practice · Brain+ retains its expectations to close additional sales contracts on CST-Therapist Companion in 2023 · In parallel, Brain+ is developing CST-Therapist Companion v2.0 as a substantial product upgrade in terms of both CST content, user customization, adaptability, and functionality and with targeted release in Denmark in H1 2024

Brain+ has convened an EGM to add a strong digital health industry profile to its board of directors

Tuesday, September 26, 2023, 8:45 CET – Brain+ A/S (Nasdaq First North: BRAINP) · Anish Shindore, a global digital health industry heavyweight with strong commercial and partnering experience as well as a vast DTx stakeholder network, has accepted to join Brain+ as new board member

Brain+ online investor meeting: Status update, warrant exercise and Q&A

Copenhagen, Denmark, September 22, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ awarded an EUopSTART grant by the Danish Innovation Fund to support 2[nd] stage of its EIC Accelerator application

Copenhagen, Denmark, September 20, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · The EUopSTART grant of up to DKK 50,000 will fund the preparations of a 2[nd] stage application for the large EIC Accelerator grant · Earlier this month, Brain+’ EIC Accelerator application for up to DKK 60 million in funding for the CST-Home Care project passed the 1[st] evaluation round with unanimous evaluator support   · The 2[nd] stage application will be submitted in October, and an answer to the application is expected in December 2023

Brain+ to present at DTx East 2023, a global summit for the digital therapeutics’ community, held in Boston, US on 26-28 September

Copenhagen, Denmark, September 13, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Brain+ founder and CEO, Kim Baden-Kristensen has been invited to give a keynote presentation at the conference on the topic of “Truly Defining Digital Therapeutics”   · The DTx conference series is the main meeting point for all key stakeholders in the global digital therapeutics’ community

Two Brain+ grant applications pass first evaluation gate with unanimous support from evaluators

Copenhagen, Denmark, September 13, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · The EIC Accelerator application of DKK 60 million in grant and equity funding, submitted in late August to support the CST-Home Care product, has passed to the 2[nd] and final evaluation round with unanimous evaluator support · The application for a DKK 4 million CO-PI grant also submitted in August to support the implementation of CST-Therapist Companion in Denmark, has passed the first screening and expanded answers have been submitted · For both grants, as well as for the InnoBooster grant, final answers are expected in Q4 2023

Brain+ secures intellectual property rights for CST-Therapist Companion in the EU and the United Kingdom

Copenhagen, Denmark, September 8, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Key design and user interface elements of CST-Therapist Companion now legally protected in the company’s first target markets via design protections · Protection of IP rights, including design elements, is very important to secure the value of a digital therapeutic and its competitive market position as well as to attract partnership agreements

Brain+ has submitted new public grant applications to raise up to DKK 67 million to develop and scale its digital dementia products

Copenhagen, Denmark, August 25, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Dementia is a field of substantial unmet needs and high political awareness, and Brain+ has a long history of successfully raising public funding to support its R&D activities · New application submitted for a Danish InnoBooster grant of DKK 3 million to complete the development of CST-Therapist Companion v2.0 · New application submitted for a CO-PI grant of DKK 4 million to support the implementation of CST-Therapist Companion in Denmark and the UK as well as in the official CST education · New application submitted for an EU EIC Accelerator grant of DKK 17 million and DKK 43 million in equity funding from the European Central Bank to develop, market and commercially scale Brain+’ CST-Home Care product

Brain+ Online Investor Update

Copenhagen, Denmark, May 22, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Brain+ and Danish municipalities are advancing the development of version 2.0 of the CST-Therapist Companion

Copenhagen, Denmark, August 9, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Since the introduction of CST-Therapist Companion v1.0 in Denmark, Brain+ has been met with a keen interest in its digital CST approach from several Danish municipalities · Municipal dementia coordinators who work with CST have joined Brain+ focus groups to provide valuable user input and concept feedback for the next version of the product · The CST-Therapist Companion v2.0 will offer upgraded technical features as well as new scalable and customizable CST content, allowing therapists to tailor the therapy to each CST group    · Feasibility testing of the CST-Therapist Companion v2.0. in a post-diagnostic care setting will begin in Q4 2023 in collaboration with the leading CST expert in Denmark, Prof. Rikke Gregersen   · Brain+ expects to have the product ready for sale in H1 2024

Breakthrough Alzheimer’s drug approval seen to renew dementia drug investments and increase the potential for digital dementia therapies – good news for Brain+

Copenhagen, Denmark, July 10, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · The US FDA has granted full approval to Lecanemab, the first ever disease modifying treatment for early Alzheimer’s disease, invented by BioArctic AB of Sweden and developed by Eisai and Biogen · Lecanemab has shown to slow brain destruction in Alzheimer’s, and after decades of drug failures in the field, experts now see a turning point to renewed investments in dementia drug research and the start of a new era of treatment · Dementia represents an immense unmet need - and there is growing acknowledgement of the role of digital approaches to compliment pharmaceutical treatments in building a more effective dementia ecosystem · Brain+ is a pioneer in the development of evidence-based digital dementia therapeutics to improve cognition in people with early Alzheimer’s dementia, and the recent industry news is seen to increase the company’s potential to attract co-development partnerships

Brain+ presents at the 5[th] Annual DTx (Digital Therapeutics) Europe conference

Copenhagen, Denmark, June 27, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“BRAINP”) today informed that the company has been invited to participate at the 5[th ]Annual DTx Europe conference to be held in London on June 28[-]29[th]. At the conference, CEO Kim Baden-Kristensen will present a Brain+ case study on ‘Managing the Need for Evidence in a DTx Start-up’, scheduled for June 28[th] at 2:10 p.m. BST (3:10 p.m. CET) and speak on a Keynote Panel Discussion on the topic of ’Is the Clinic Ready for DTx?’, on June 29[th] at 9:00 a.m. BST (10:00 a.m. CET).

Brain+ showcased at Danish Dementia Days and at Altenpflege in Germany, Europe’s largest elderly care conference

Copenhagen, Denmark, May 23, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Brain+ was featured at The Dementia Days in Copenhagen, the most important annual dementia event in Denmark with over 1,000 municipal dementia coordinators present · Brain+ was selected as one of the most promising new elderly care technology start-ups at the annual German elderly care conference, Altenpflege   · Conference showcasing is essential to build product awareness and relationships with target customers – and has confirmed growing interest in the Brain+ dementia products  

Brain+ closes its second sales contract for CST – Therapist Companion with a dementia care center in Gladsaxe municipality

Copenhagen, Denmark, May 10, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Gladsaxe is the second Danish municipality to have opened for use of CST – Therapist Companion to support Cognitive Stimulation Therapy (CST) for people with dementia · Two contract closings less than 6 months after CST - Therapist Companion was commercially introduced is promising, considering a typical municipal sales cycle of 12-24 months · Denmark is an important reference market for Brain+ with CST gaining widespread recognition

Brain+ Online Investor Update

Copenhagen, Denmark, May 8, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)

Malteser Hilfsdienst and Brain+ begin collaboration to offer people with dementia access to CST in special dementia cafes in Germany

Copenhagen, Denmark, April 21, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · The first step is a 2-month pilot offering of Brain+’ German version of CST-Therapist Companion in one Malteser dementia café to support care services for people with dementia. · Malteser Hilfsdienst is a key provider of dementia services, and the potential is to expand the use of CST-Therapist Companion to the organization’s 100 dementia cafés around Germany.

Germany sets a new digitalization strategy, further supporting the adoption of digital therapeutics in Europe’s largest healthcare market

Copenhagen, Denmark, March 28, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Germany represents a large market potential for Brain+’ digital dementia therapeutics · Brain+ is preparing for commercial introduction of its first digital dementia product, CST-Therapist Companion, in Germany in the 2[nd] quarter of 2023 · As an important healthcare reference country, Germany’s strong digitalization commitment sets the stage for a more rapid adoption of digital therapeutics across Europe

Cognitive Stimulation Therapy (CST) enhances the effects of Alzheimer’s disease medicine

Copenhagen, Denmark, March 24, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · CST in combination with cholinesterase inhibitors shows to be more effective against dementia in Alzheimer’s disease (AD) than medicine alone · This is promising for combining Brain+ CST products with AD medicine in multi-modal treatment plans to improve health outcomes for patients · Combination treatments could enhance the value of product portfolios for pharmaceutical companies and could thus lead to strategic partnerships for Brain+

Brain+ expands its first sales contract, close to doubling it

Copenhagen, Denmark, March 20, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · This is important because it shows the potential for growing engagements with customers after an initial contract has been established · The contractual expansion happens only 3 months after the closing of the sale in December 2022 · Denmark is an important reference market for Brain+, and the total municipal market potential for the full future suite of Brain+ CST-based products is estimated at 200 million DKK

Respected dementia experts and Brain+ gets EU grant to research how to optimize digital at-home treatments for people with dementia

Copenhagen, Denmark, March 14, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · The grant covers research into the two main therapeutic technologies of Brain+, digitalized Cognitive Stimulation Therapy (CST), and Computerized Cognitive Training (CCT). · The grant will also examine the hypothesized synergy effects of combining CST with CCT, which is a key research step for the third Brain+ product in the pipeline, ‘CST-for-MCI’. · University of Gothenburg is hosting the grant, which has a budget of €48,405, and is funded by the EU Joint Programme - Neurodegenerative Disease Research.

New Cochrane review confirms the benefit and relevance of Cognitive Stimulation Therapy (CST) for people with dementia

Copenhagen, Denmark, March 2, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) · Reviews carried out by Cochrane Review Groups are recognized worldwide as the highest standard in evidence-based healthcare · The review shows cognitive benefits of CST corresponding to a 6-month delay in cognitive decline in mild to moderate dementia, and additional improvements in communication and social interaction · Provides further solid support for the increased adoption of CST as a non-pharmaceutical dementia therapy worldwide and for Brain+’ CST-based suite of digital dementia products 

Brain+ showcases its digital dementia products at the Danish-Japanese Welfare and Health Tech Business Conference

Copenhagen, Denmark, February 21, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · Important opportunity for Brain+ to present its innovative digital solutions for better care and treatment of Alzheimer’s and other types of dementia to key Japanese industry and academic stakeholders. · With a large aging population and more than 4.6 million people living with dementia, Japan has a strong focus on new treatment options and represents a highly attractive market opportunity for Brain+.

Brain+ completes Swedish research version of its dementia product with the Research Institutes of Sweden and extends the collaboration

Copenhagen, Denmark, January 26, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · A Swedish language version of Cognitive Stimulation Therapy has been created in collaboration with the Research Institutes of Sweden (RISE) in the AD-Shield project. · This will enable further R&D work with our Swedish partner research network, including Research Institutes of Sweden (RISE), University of Gothenburg: the Department of Applied IT, Sahlgrenska Academy, and AgeCap. · An in-house usability study of the CST product at RISE yielded new recommendations for enhancing User Interaction (UI) design further. · Brain+ extended its collaboration with RISE via a key academic partner of Brain+, Associate Professor Rob Lowe, who has moved to RISE, and retains faculty status at the University of Gothenburg.

Results from a clinical study provide promising feasibility indications for Brain+’ CCT technology for cognitive training

Copenhagen, Denmark, January 11, 2023 – Brain+ A/S (Nasdaq First North: BRAINP) • The results of an 8-week placebo-controlled intervention study in people with Subjective Cognitive Impairments (SCI) demonstrated improved cognitive load after the use of Brain+' Computerized Cognitive Training (CCT) games • Some far-transfer effects of the CCT training were also seen in the participant's performance in a shopping task • The indications of clinical feasibility of the CCT technology and the Starry Night cognitive test, provide early support for the Company's pipeline product for Mild Cognitive Impairment, which combines CCT, Starry Night, and Cognitive Stimulation Therapy (CST)

Brain+ closes 2022 with the first municipal sale of its new dementia product and begins the monetization journey

Copenhagen, Denmark, December 31, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · The sale covers the use of the ‘basic package’ of the CST-Therapist Companion in one training facility for three years, in the municipality of Herning, at an introductory price of 50.000 DKK. · This sale happens already within 2 months of market introduction in what is normally a municipal sales cycle of 6-18 months. A number of customer dialogues are ongoing. · The total market potential in Denmark is valued at 200 million DKK, in the range of ~250.000-10 million DKK per municipality. These estimates are based on the full future portfolio of Brain+ digital dementia products and services.

3-year innovation project with the Danish Life Science Cluster is completed with the Brain+ CST-Therapist Companion product as the final output

Copenhagen, Denmark, December 28, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · The 3-year ‘CIRCULAR Co-Creation’ project has been the backbone of the development of all the Brain+ Cognitive Stimulation Therapy (CST) products and has resulted in the first Brain+ digital CST prototype, and ultimately in the first Brain+ CST dementia product, the CST-Therapist Companion. · The project has additionally given deep hands-on experience with delivering digital CST to people with dementia, both at home and in group settings in the clinic. This experience has been crucial for adapting the CST-Therapist Companion product to the user's needs and the delivery setting. · In particular, the project involved a team of researchers led by Rikke Gregersen, Ph.D., senior associate professor at the Research Program for Dementia at VIA University College. Rikke Gregersen is a leading expert and key opinion leader on CST in Denmark. Rikke Gregersen has adapted and translated the original English CST manual into Danish and played a key role in bringing CST to Denmark, and in this project in adapting CST to the digital format.

Brain+ announces Investor Webinar following strong Q4 with product launch and successful capital raise

Copenhagen, Denmark, December 22, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ invites you to an investor webinar after a strong quarter with commercial introduction of its first dementia product, a successful capital raise, and several supportive market news announcements

Brain+ begins commercial pilot with volunteers from the DaneAge Association

Copenhagen, Denmark, December 16, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · Volunteers play a key role in caring for people with dementia in target markets like Denmark, Germany, United Kingdom · The pilot project will test the use of the Brain+ product, ‘CST[1]-Therapist Companion’, in a use case where a volunteer facilitates CST sessions with elderlies at home in a one-to-one setting (as opposed to group-based CST). This explores a new commercial opportunity (volunteer services use of CST) and benefits product R&D for the at-home use product, 'CST-Home Care'. · DaneAge (Ældre Sagen), counting 930.000 members, uses volunteers to care for both elderlies and people with dementia

Brain+ completes the implementation of an ISO 13485 Quality Management System for Medical Devices

Copenhagen, Denmark, December 14, 2022 – Brain+ A/S (Nasdaq First North: BRAINP) · Having a standardized Quality Management System in place is a key requirement for the development and commercialization of compliant digital therapeutics · Meeting this milestone supports the company’s objective to attract large pharma partnerships and ensure product reimbursement at scale